Mount Sinai Adopts SOPHiA GENETICS’ AI DDM Platform for 4,000+ Cancer Patients
Mount Sinai Health System will deploy SOPHiA GENETICS' AI-powered DDM Platform to enhance next-generation sequencing for blood cancers and solid tumors, supporting more than 4,000 oncology patients annually. Its AI-driven analytics consolidate analysis steps, cut manual interpretation time and deliver genomic insights across a network of more than 990 institutions.
1. Collaboration Overview
Mount Sinai Health System will implement the SOPHiA DDM Platform in its Molecular Pathology labs to strengthen genomic testing capabilities for blood cancers and solid tumors, leveraging AI-driven analytics to support over 4,000 oncology patients annually.
2. Technical Benefits of SOPHiA DDM
The platform consolidates critical steps in the next-generation sequencing analysis pipeline, reduces manual interpretation time and enhances detection and interpretation of complex genomic variants, enabling faster turnaround and optimized laboratory resource allocation.
3. Network Expansion and Strategic Impact
With this adoption, Mount Sinai joins more than 990 global institutions using SOPHiA’s decentralized platform, furthering SOPHiA GENETICS’ mission to democratize data-driven precision medicine and potentially expanding its commercial footprint in the oncology diagnostics market.